Dapagliflozin >10 mg provides added benefits in haematocrit, SBP, albuminuria, uric acid
Dapagliflozin therapy with doses higher than 10 mg appears to deliver greater beneficial effects in haematocrit, systolic blood pressure, urinary albumin–creatinine ratio, and uric acid, with no evident increases in the rate of adverse events, a recent study has shown.
Dapagliflozin >10 mg provides added benefits in haematocrit, SBP, albuminuria, uric acid
20 Nov 2020